会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明申请
    • IMPROVED METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME
    • 用于诊断急性冠状动脉综合征的改进方法
    • WO2005073727A1
    • 2005-08-11
    • PCT/FI2005/000036
    • 2005-01-19
    • QIN, Qiu-PingPETTERSSON, Kim
    • QIN, Qiu-PingPETTERSSON, Kim
    • G01N33/573
    • C07K16/40G01N33/6893G01N2333/471G01N2800/324Y10T436/25125Y10T436/255
    • This invention concerns a bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), wherein free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Furthermore, the invention concerns a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.
    • 本发明涉及用于定量测定游离PAPP-A的样品的生物亲和力测定法,其定义为与主要碱性蛋白质(proMBP)的形式不复合的妊娠相关血浆蛋白A(PAPP-A),其中游离PAPP- A确定i)作为测量的总PAPP-A与与proMBP复合的测量的PAPP-A之间的计算差异,或ii)通过仅测量游离PAPP-A的直接生物亲和测定。 此外,本发明涉及一种通过使用游离PAPP-A作为标记或者无比PAPP-A /总PAPP-A,游离PAPP-A / PAPP-A复合的标记物来诊断人的急性冠状动脉综合征的方法 proMBP或PAPP-A与proMBP /总PAPP-A复合。
    • 14. 发明申请
    • BIOANALYTICAL ASSAY
    • 生物分析
    • WO0244725A8
    • 2002-10-17
    • PCT/FI0101024
    • 2001-11-26
    • INNOTRAC DIAGNOSTICS OYPETTERSSON KIM
    • PETTERSSON KIM
    • B82B1/00G01N33/53G01N33/543G01N33/545
    • G01N33/54346Y10T428/2982
    • The present invention relates to a nanoparticle comprising a specific binding reactant, said nanoparticle being useful for determining an analyte to which analyte or complex comprising said analyte said binding reactant is specific. Characteristic for the nanoparticle is that the diameter of said nanoparticle is less than 200 nm, said nanoparticle is coated with multiple said specific binding reactants to the extent that the affinity constant of said nanoparticle towards said analyte essentially exceeds that of free said binding reactant towards said analyte and/or the association rate constant between said nanoparticle and said analyte essentially exceeds the association rate constant between free said binding reactant and said analyte; and said nanoparticle comprises a detectable feature. The invention also relates to biochemical assays using said nanoparticle. The assay further relates to a proximity based homogenous assay comprising a first group labeled with an energy donating compound (donor) and a second group labeled with an energy accepting compound (acceptor), wherein the donor is luminescent and has a long excited state lifetime and the acceptor is luminescent having a short or long excited state lifetime or the acceptor is non-luminescent, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between said groups, is measured. Characteristic for the assay is that the donor is a nanoparticle.
    • 本发明涉及包含特异性结合反应物的纳米颗粒,所述纳米颗粒可用于确定包含所述分析物的分析物或复合物的分析物,所述分析物所述结合反应物是特异性的。 纳米颗粒的特征在于所述纳米颗粒的直径小于200nm,所述纳米颗粒用多种所述特异性结合反应物涂覆至所述纳米颗粒对所述分析物的亲和常数基本上超过所述游离的所述结合反应物对所述 所述纳米颗粒与所述分析物之间的分析物和/或缔合速率常数基本上超过游离所述结合反应物与所述分析物之间的缔合速率常数; 并且所述纳米颗粒包含可检测特征。 本发明还涉及使用所述纳米颗粒的生物化学测定。 该测定还涉及基于接近度的均相测定法,其包含用供能化合物(供体)标记的第一组和用能量受体化合物(受体)标记的第二组,其中供体是发光的并且具有长激发态寿命和 受主发光具有短的或长的激发态寿命或者受体不发光,并且分别在从供体到受体的能量转移中分别由缩短或延长 所述组,是测量的。 测定的特征是供体是纳米颗粒。